Oncohema Key

Drug Target Stage of development and indications Company mTOR Sirolimus (rapamycin) mTOR Approved for renal transplant, phase II/III trials for MM, NHL Pfizer Temsirolimus (CCI779) mTOR Approved for RCC and…

Pathway alteration Incidence Tumor type References mTOR overexpression 6/9 (67 %) pNET Shida et al. [11] Mutations in PTEN, TSC2, PIK3CA 10/68 (15 %) pNET Jiao et al. [12] Akt…

1. Serum LDH > 1.5 times the upper limit of normal 2. Hemoglobin level < lowest limit of normal 3. Corrected serum calcium level > 10 mg/dL (2.5 mmol/L) 4. Interval of less than 1 year…